Zealand Pharma Secures $5.3B to Pioneer Next-Generation Peptide Innovations

Zealand Pharma, a pioneering Danish biotechnology company committed to revolutionizing patient care with next-generation peptide medicines, is thrilled to announce a monumental funding milestone of 5,300,000,000 raised. This significant investment underscores the strong confidence that investors have in Zealand’s mission and innovative approach to drug development. With a strategic focus on discovering and developing cutting-edge peptide drugs, Zealand has already seen impressive progress with over 10 drug candidates advancing into clinical trials and two reaching the market. This funding will further accelerate the development of their promising internal pipeline that primarily targets specialty gastrointestinal and metabolic diseases, offering hope to patients who urgently need new treatment options. The capital infusion is set to bolster Zealand Pharma’s ongoing research and development efforts, enabling the expansion of clinical trials and expediting the journey of novel therapeutics from the lab to the clinic. Additionally, the funding is expected to enhance existing collaborative partnerships, such as the clinical license collaboration with Boehringer Ingelheim and the pre-clinical license collaboration with Alexion Pharmaceuticals, reinforcing Zealand’s commitment to innovation and excellence in biopharmaceutical research. By strengthening these collaborations and investing further in its robust development programs, Zealand reaffirms its dedication to transforming lives through science and innovation. Based in Copenhagen (Søborg), Denmark, Zealand Pharma continues to bond with its partners, scientists, and patients as it drives forward a new era of peptide medicines. For more insights into their breakthrough work and future initiatives, visit www.zealandpharma.com or connect with them on LinkedIn to learn how Zealand Pharma is shaping the future of healthcare.